191 related articles for article (PubMed ID: 15583794)
1. Dendritic cells and HNSCC: a potential treatment option? (Review).
Dunn G; Oliver KM; Loke D; Stafford ND; Greenman J
Oncol Rep; 2005 Jan; 13(1):3-10. PubMed ID: 15583794
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in head and neck cancer: current practice and future possibilities.
Agada FO; Alhamarneh O; Stafford ND; Greenman J
J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
Bron L; Romero P
Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
[TBL] [Abstract][Full Text] [Related]
4. A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.
Weise JB; Maune S; Görögh T; Kabelitz D; Arnold N; Pfisterer J; Hilpert F; Heiser A
Auris Nasus Larynx; 2004 Jun; 31(2):149-53. PubMed ID: 15121224
[TBL] [Abstract][Full Text] [Related]
5. Maturation of dendritic cells in the presence of living, apoptotic and necrotic tumour cells derived from squamous cell carcinoma of head and neck.
Kacani L; Wurm M; Schwentner I; Andrle J; Schennach H; Sprinzl GM
Oral Oncol; 2005 Jan; 41(1):17-24. PubMed ID: 15598581
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells pulsed with GST-EGFR fusion protein: effect in antitumor immunity against head and neck squamous cell carcinoma.
Yang BB; Jiang H; Chen J; Zhang X; Ye JJ; Cao J
Head Neck; 2010 May; 32(5):626-35. PubMed ID: 19787789
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy for head and neck squamous cell carcinoma].
Bron L; Romero P
Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck squamous cell carcinomas and the ability of these CD34+ cells to differentiate into immune stimulatory dendritic cells.
Lathers DM; Achille N; Kolesiak K; Hulett K; Sparano A; Petruzzelli GJ; Young MR
Otolaryngol Head Neck Surg; 2001 Sep; 125(3):205-12. PubMed ID: 11555755
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?
Alhamarneh O; Amarnath SM; Stafford ND; Greenman J
Head Neck; 2008 Feb; 30(2):251-61. PubMed ID: 18172882
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
11. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
12. Cytokines in head and neck cancer.
Pries R; Wollenberg B
Cytokine Growth Factor Rev; 2006 Jun; 17(3):141-6. PubMed ID: 16540364
[TBL] [Abstract][Full Text] [Related]
13. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma.
Kerrebijn JD; Simons PJ; Balm AJ; Tas M; Knegt PP; de Vries N; Tan IB; Drexhage HA
Head Neck; 1996; 18(4):335-42. PubMed ID: 8780944
[TBL] [Abstract][Full Text] [Related]
14. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
Ferris RL
ORL J Otorhinolaryngol Relat Spec; 2004; 66(6):332-40. PubMed ID: 15668533
[TBL] [Abstract][Full Text] [Related]
15. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Strauss L; Volland D; Kunkel M; Reichert TE
Med Sci Monit; 2005 Aug; 11(8):BR280-92. PubMed ID: 16049374
[TBL] [Abstract][Full Text] [Related]
16. [Future Prospects on neoplasm antigen vaccine therapy for patients with head and neck squamous cell carcinoma].
Eura M
Nihon Jibiinkoka Gakkai Kaiho; 2002 Mar; 105(3):201-7. PubMed ID: 12014346
[No Abstract] [Full Text] [Related]
17. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
19. Functional alteration of myeloid dendritic cells through head and neck cancer.
Brocks CP; Pries R; Frenzel H; Ernst M; Schlenke P; Wollenberg B
Anticancer Res; 2007; 27(2):817-24. PubMed ID: 17465207
[TBL] [Abstract][Full Text] [Related]
20. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
